Eyebot Raises $20M to Scale 90-Second Vision Kiosks

Eyebot secures $20M to scale doctor-verified 90-second vision kiosks

Eyebot, a Boston startup founded in 2021, announced a $20 million Series A round as it moves from pilots to broad commercialization. The company’s kiosks deliver a free, 90-second vision test and generate prescriptions that are reviewed and approved by licensed eye doctors, combining speed with clinical oversight.

The fresh funding brings Eyebot’s total raised to over $30 million. Led by General Catalyst with participation from returning investors, the round will expand kiosk deployment, grow clinical operations, and scale commercial partnerships with retailers and other venue hosts.

Eyebot’s kiosks are already in high-traffic locations — malls, universities, retail stores, pharmacies, grocery chains, schools and airports — where users can stop for a quick test. Since the seed round in June 2024, Eyebot reports more than 45,000 free vision tests and says it’s on track to deliver over half a million tests a year.

What differentiates the product is the clinical layer: every test result is reviewed by experienced doctors and prescriptions are issued under clinical supervision. If a kiosk flags an unusual result, users are referred for a comprehensive in-person exam, preserving patient safety and regulatory alignment.

Eyebot’s go-to-market model mixes consumer-first access with commercial partnerships. Tests are free; prescriptions are doctor-verified (for a fee), and kiosks are leased to optical retailers, eyewear brands, and independent practices. The model aims to drive retail foot traffic while lowering friction to basic vision care.

Adoption has quieted early skepticism from providers worried about accuracy. Eyebot’s emphasis on physician review and referral pathways helped build trust, and the company reports surprising uptake among parents testing children during errands — a sign of true consumer convenience.

Investors and backers see a convergence of healthcare access and retail experience. With the Series A, Eyebot plans to double down on product development, clinical operations, and commercial growth while scaling revenue and deployments nationwide.

• High-traffic retail placements accelerate consumer trials and prescription conversions.
• Doctor-reviewed results help address regulatory and provider concerns about accuracy.
• A leasing model opens revenue streams for venues and lowers capital hurdles for partners.
• Rapid testing at convenient locations could close care gaps for kids and busy adults.

For retailers, health systems, and campus operators, Eyebot represents a new touchpoint that blends commerce with preventive care. The company’s challenge now is to sustain clinical quality, integrate with partner operations, and prove predictable economics as deployments scale.

QuarkyByte’s approach to these kinds of rollouts is to pair operational analytics with clinical validation roadmaps and partner ROI models. That means mapping optimal kiosk sites by foot traffic and demographics, simulating prescription conversion paths, and designing clinical escalation workflows to keep compliance tight while maximizing access.

Eyebot’s $20M raise signals investor confidence in fast, clinically supervised point-of-care tech. If the company can prove consistent clinical outcomes and predictable economics at scale, these kiosks could become a common first step in routine vision care — and a visible example of how connected devices can expand access.